Introduction
The impact of drugs on intracellular targets of efficacy and/or toxicity, and susceptibility to elimination, is driven by local unbound concentrations (C unbound ) according to the "free drug hypothesis" (Smith et al., 2010) . Prediction of clinical efficacy, toxicity and drug-drug interactions (DDIs) could be improved by accounting for C unbound in vitro and in vivo (Zhou et al.,
7 whole tissue (Li et al., 2009; Tchaparian et al., 2011) , however, the use of medium additives can modulate expression levels to more closely mimic the in vivo situation (Swift et al., 2010) .
Methods to estimate the cellular unbound fraction (f u ) and resulting Kp u,u in hepatocyte models in vitro include the use of temperature, inhibitors, and/or pharmacokinetic modeling (Parker and Houston, 2008; Yabe et al., 2011; Jones et al., 2012; Shitara et al., 2013) , but direct measurement of Kp u,u in SCH has not been reported.
The objective of this work was to determine the intracellular C unbound and subcellular localization of drugs in SCH compared to IPL tissue. A set of probe drugs with distinct mechanisms of hepatocellular uptake and accumulation was selected for investigation.
Ritonavir inhibits drug transport and metabolism in vitro and in vivo, and accumulates in liver tissue (Denissen et al., 1997) . Surprisingly, the contribution of active transport to the cellular uptake and accumulation of ritonavir has not been characterized definitively, and reports of hepatic Kp u,u and intracellular C unbound for prediction of ritonavir DDIs are inconsistent (Parker and Houston, 2008; Griffin et al., 2011; Mateus et al., 2013; Pfeifer et al., 2013) . Rosuvastatin, an HMG-CoA reductase inhibitor with a primary site of action in hepatocytes, is taken up efficiently by OATPs and accumulates within hepatocytes, with a Kp u,u >1 (Nezasa et al., 2002a; Nezasa et al., 2003; Yabe et al., 2011; Shitara et al., 2013) . Furamidine is formed in the liver via sequential metabolism from the prodrug, pafuramidine; furamidine is poorly permeable and must be excreted from hepatocytes into the systemic circulation to exert antiparasitic activity (Paine et al., 2010; Yan et al., 2011) . This set of drugs provided a useful range of tissue accumulation, hepatic f u , subcellular distribution, and Kp u,u values for comparison of methods to determine hepatocellular C unbound .
Materials and Methods

Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Rosuvastatin (Nezasa et al., 2002b) and the deuterated internal standard (d 6 -rosuvastatin), as well as ritonavir (Denissen et al., 1997) were purchased from Toronto
Research Chemicals (Toronto, ON, Canada). Furamidine, the prodrug pafuramidine, and internal standard (deuterium-labeled furamdine) were synthesized in the laboratory of Dr. David W. Boykin, as reported previously (Yan et al., 2011) .
Tissue Accumulation.
Male Wistar rats (Charles River Labs, Wilmington, MA) were used for IPL studies. Rats were allowed free access to water and food, and acclimated for a minimum of 1 week prior to Radiolabeled Chemicals, Inc., St. Louis, MO) for 10 min at 37°C as described previously (Swift et al., 2010) . Starting on day 3, pafuramidine was incubated for 24 h at 10 μ M to allow complete formation and equilibration of furamidine, as previously reported (Yan et al., 2011) , followed by a 5-min incubation in Ca 2+ -free HBSS. In all cases, incubation medium was collected at the end of the incubation period, and cells were washed three times in ice-cold HBSS.
Fractionation.
Liver tissue was homogenized in 3-5 volumes of fractionation buffer [250 mM sucrose, 10 mM HEPES, 10 mM KCl, 1 mM EDTA, 1.5 mM MgCl 2 , 1 mM DTT, cOmplete ® Protease
Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN)] using a Potter-Elvehjem homogenizer.
Following treatment with the drug of interest, all wells of the 6-well SCH plate were harvested and pooled by scraping each well sequentially into 1 mL fractionation buffer. Collected cells in buffer were homogenized by passing 10 times through a 27g needle, resting 10 min on ice, followed by an additional 10 passes. Following homogenization to disrupt cell membranes, the resulting crude lysates (liver and SCH) were sampled and reserved to perform analysis for total and unbound drug concentrations, protein content and enzyme activity assays. organelle-specific enzyme activity detected in each subfraction compared to the whole lysate.
Binding.
Binding was determined in whole tissue lysates and cytosolic fractions by equilibrium dialysis. Initial studies were performed to determine the time to equilibrium and test for protein leakage or potential volume shifts with whole liver tissue (data not shown). Aliquots were loaded into a 96-well equilibrium dialysis apparatus (HTDialysis, LLC; Gales Ferry, CT) and dialyzed against phosphate buffer for 6 h with shaking at 37°C. Binding replicates (n=3)
consisted of 3-fold dilutions of each sample (1-, 3-, and 9-fold original sample). The unbound fraction (f u ) was back-extrapolated to account for dilution during the homogenization/fractionation process, as well as subsequent dilutions, as described previously (Kalvass et al., 2007) :
This approach provides the best precision in the linear range, and that precision is lost when the measured unbound fraction becomes high (f u,measured >80%). In cases where f u,measured was >80%
at the lowest dilution, the value was reported as "greater than" the undiluted f u , calculated according to the equation above.
Sample Analysis
Ritonavir, rosuvastatin and furamidine were quantified by LC-MS/MS as described previously; rosuvastatin was quantified by liquid scintillation counting for SCH studies (Abe et al., 2008; Rezk et al., 2009; Lee and Brouwer, 2010; Yan et al., 2011 Following fractionation of SCH lysates, the majority of membrane-bound organelles (including mitochondria and microsomes) were recovered in the initial low-speed spin (600xg). Cytosolic separation and recovery was efficient and successful, as shown in Figure 2D with ~90% of the total LDH activity in the crude lysate recovered in the cytosolic fraction of SCH lysates.
Recovery of the probe drugs in all fractions was compared to the total mass in the whole lysate prior to fractionation. Recovery of probe drugs after fractionation of whole liver tissue and SCH was approximately 100% (±10%). The average subcellular distribution of each drug in whole tissue and SCH is shown in Figure 3 . In all cases, the coefficient of variation was less than 20% when at least 10% of the drug was recovered in a given fraction. In whole liver tissue, approximately 36% of the ritonavir was found in the cytosolic fraction, 31% in the microsomal fraction, and 18% in the mitochondrial fraction, with the remainder distributed fairly evenly among the remaining fractions. In SCH lysates, cytosolic recovery of ritonavir was similar to that in whole liver tissue (43% 
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Discussion
The present study evaluated an organ-specific in vitro model system to estimate C unbound , and predict cellular partitioning and accumulation of drugs. The SCH system exhibits properly localized and functional transport proteins, metabolic and regulatory machinery. This system may be able to recapitulate the relevant cellular disposition of drugs whose distribution is influenced by the interplay of these processes in hepatocytes in vivo.
Total accumulation (Kp observed ) in whole tissue was well predicted by the SCH model Tc-mebrofenin in humans (Pfeifer et al., 2013) . This apparent in vitro-in vivo disconnect was reconciled by accounting for the C unbound of ritonavir in hepatocytes relative to its inhibitory potency against MRP2 (Pfeifer et al., 2013) , and highlights the importance of estimating accurately the relevant hepatocellular C unbound to predict potential DDIs.
Rosuvastatin accumulation in whole liver (Kp observed = 33) and SCH (Kp observed = 17) was in good agreement with previous reports of 18-to 45-fold hepatic accumulation after oral administration in rats (Nezasa et al., 2002b) , and 15-fold accumulation in isolated hepatocytes (Nezasa et al., 2003) . Although rosuvastatin binding did account for a portion of tissue accumulation (Kp predicted ~3-4), the majority of accumulation was due to unbound drug (Kp u,u of 8 to 11), consistent with efficient hepatic uptake and rate-limited efflux, and previous Kp u,u values ranging from ~10-60 in vitro (Nezasa et al., 2003; Yabe et al., 2011; Shitara et al., 2013) .
Rosuvastatin binding data in SCH demonstrated a limitation associated with the required dilution of small in vitro tissue samples when performing these studies. For compounds such as rosuvastatin that are not extensively bound (f u,measured >80%), dilution of SCH samples upon collection resulted in observed binding data that were difficult to extrapolate accurately.
Therefore, the resulting Kp u,u value in SCH is a conservative minimum and potentially underestimates the true value. However, the observed SCH f u,lysate >36±3% is similar to 48%
reported previously in suspended hepatocytes (Yabe et al., 2011) , so the reported Kp u,u >5-6 from SCH (Table 1) is likely less than a 2-fold underestimate, and still indicates the contribution of active uptake.
Extensive hepatic accumulation of the active metabolite, furamidine, was observed in both rat IPLs and SCH, as reported previously (Yan et al., 2011) . Previous studies using differential centrifugation to separate fractions revealed that furamidine was localized primarily A number of potential limitations are associated with the subcellular fractionation approach, including: a) Some degree of cross-contamination among isolated cellular fractions.
This can be assessed primarily by recovery of marker enzyme activity specific for each organelle, but adds significant time-and labor-intensive efforts to sample analysis. The recovery of acid phosphatase activity in multiple fractions ( Fig. 2A) , 2013) . The assumption of the latter method is that all active processes are inert at 4°C, and that cellular accumulation represents passive equilibration of unbound drug.
However, the effect of temperature and potential artifacts on non-specific binding (Igari et al., 1981; Kodama et al., 1999; Zeitlinger et al., 2011) and membrane fluidity and partitioning (Herbette et al., 1983; Palmeira and Oliveira, 1992; Liu et al., 2001 ) are well-established. The methods applied to rat SCH in the present investigation to determine intracellular C unbound and Kp u,u were reported recently in immortalized (HEK293) cells (Mateus et al., 2013) , which lack the full complement of mechanisms present in hepatocytes that influence cellular accumulation (e.g., active uptake, metabolism, and biliary excretion). Data are expressed as % total activity in the initial lysate recovered in each pellet; mean±SD of n=3 (whole liver) or n=9 (SCH) (see Methods for more details). 
